Leserbrev

• Daniëla Maria Hinke; Sofie R. Dorset; Eirik Bratland et al. (2025). CXCR2 deficiency with myelokathexis caused by a novel variant: Correction via CRISPR/Cas. (ekstern lenke)
• Sahba Shafiee; Pascal Francois Gelebart; Mihaela-Lucia Popa et al. (2021). Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. (ekstern lenke)
• Astrid Marta Olsnes Kittang (2025). Allogen stamcelletransplantasjon ved lymfom – kan vi kurere flere?. (ekstern lenke)

Vitenskapelig artikkel

• Kari Busterud; Mats Remberger; Pål Tore Bentsen et al. (2025). Allogeneic stem cell transplantation for acute myeloid leukaemia 2005–22. (ekstern lenke)
• Panagiotis Baliakas; Bianca Tesi; Ulla Wartiovaara-Kautto et al. (2019). Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. (ekstern lenke)
• Ann-Helen Kristoffersen; Carola Elisabeth Henriksson; Astrid Marta Olsnes Kittang et al. (2022). Monitorering av ufraksjonert heparin. (ekstern lenke)
• Astrid Marta Olsnes; Elisabeth Ersvær; Anita Ryningen et al. (2009). The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. (ekstern lenke)
• Håkon Reikvam; Kimberley Joanne Hatfield; Anne Margrete Øyan et al. (2009). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. (ekstern lenke)
• Luca Cassetta; Kirsten Bruderek; Joanna Skrzeczynska-Moncznik et al. (2020). Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. (ekstern lenke)
• Silje Johansen; Ingvild Jenssen Lægreid; Siw Leiknes Ernstsen et al. (2021). Thrombosis and thrombocytopenia after HPV vaccination. (ekstern lenke)
• Kristoffer Sand; Jakob Theorell; Øystein Bruserud et al. (2016). Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes. (ekstern lenke)
• Jan-Lukas Førde; Ingeborg Nerbø Reiten; Kari Espolin Fladmark et al. (2022). A new software tool for computer assisted in vivo high-content analysis of transplanted fluorescent cells in intact zebrafish larvae. (ekstern lenke)
• Anna Norberg; Anna Rosén; Klas Raaschou-Jensen et al. (2018). Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. (ekstern lenke)
• Astrid Marta Olsnes; Kimberley Joanne Hatfield; Øystein Bruserud (2009). The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. (ekstern lenke)
• Håkon Reikvam; Astrid Marta Olsnes Kittang; Guro Kristin Melve et al. (2013). Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?. (ekstern lenke)
• Maria Karolina Jonsson; Daniel Hammenfors; Oddvar Oppegaard et al. (2015). A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura. (ekstern lenke)
• Astrid Marta Olsnes Kittang; Kristoffer Sand; Annette Brenner et al. (2016). The systemic profile of soluble immune mediators in patients with myelodysplastic syndromes. (ekstern lenke)
• Nessar Ahmad Azrakhsh; Patrycja Mensah-Glanowska; Kristoffer Sand et al. (2019). Targeting immune signaling pathways in clonal hematopoiesis. (ekstern lenke)
• Eileen Wedge; Jakob Werner Hansen; Ingunn Dybedal et al. (2021). Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. (ekstern lenke)
• Alenka Djarmila Behsen; Esten Nymoen Vandsemb; Tobias Schmidt Slørdahl et al. (2025). T cell phenotype and clonality changes in myeloma patients with short overall survival. (ekstern lenke)
• Håkon Reikvam; Astrid Marta Olsnes; Bjørn Tore Gjertsen et al. (2009). Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. (ekstern lenke)
• Kristoffer Sand; Kristin Paulsen Rye; Bård Mannsåker et al. (2013). Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. (ekstern lenke)
• Håkon Reikvam; Kimberley Joanne Hatfield; Anne Margrete Øyan et al. (2010). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. (ekstern lenke)
• Astrid Marta Olsnes Kittang; Shahram Kordasti; Kristoffer Sand et al. (2016). Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. (ekstern lenke)
• Elisabeth Ersvær; Jian-Ying Zhang; Emmet Martin McCormack et al. (2007). Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. (ekstern lenke)
• Elisabeth Ersvær; Astrid Marta Olsnes; Øystein Bruserud (2007). The Immunological Dilemma: Cellular Innate and Adaptive Immune Response Versus Human Acute Myeloid Leukemia. (ekstern lenke)
• Magnus Tobiasson; Tatjana Pandzic; Johanna Illman et al. (2024). Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation. (ekstern lenke)
• Bengt Rasmussen; Lars Nilsson; Magnus Tobiasson et al. (2025). Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. (ekstern lenke)
• Magnus Tobiasson; Ingunn Dybedal; Mette Skov Holm et al. (2014). Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. (ekstern lenke)
• Cristina A. Tentori; Lin P. Zhao; Benedetta Tinterri et al. (2024). Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium. (ekstern lenke)
• Hanne Kristin Fredly; Elisabeth Ersvær; Astrid Marta Olsnes Kittang et al. (2013). The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. (ekstern lenke)
• Astrid Marta Olsnes; Dmitri Motorin; Anita Ryningen et al. (2006). T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). (ekstern lenke)
• Bengt Rasmussen; Gudrun Göhring; Elsa Bernard et al. (2022). “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”. (ekstern lenke)
• Astrid Marta Olsnes; Anita Ryningen; Elisabeth Ersvær et al. (2008). In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. (ekstern lenke)
• Øystein Bruserud; Anita Ryningen; Astrid Marta Olsnes et al. (2007). Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. (ekstern lenke)
• Håkon Reikvam; Kimberley Joanne Hatfield; Philippe Lassalle et al. (2010). Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Øystein Bruserud; Håkon Reikvam; Astrid Marta Olsnes Kittang et al. (2012). High-dose etoposide in allogeneic stem cell transplantation. (ekstern lenke)
• Nikoleta Bizymi; Sunčica Bjelica; Astrid Marta Olsnes Kittang et al. (2019). Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. (ekstern lenke)
• Kimberley Joanne Hatfield; Astrid Marta Olsnes; Bjørn Tore Gjertsen et al. (2005). Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. (ekstern lenke)
• Øystein Bruserud; Elisabeth Ersvær; Astrid Marta Olsnes et al. (2008). Anticancer Immunotherapy in Combination with Proapoptotic Therapy. (ekstern lenke)
• Håkon Reikvam; Hanne Kristin Fredly; Astrid Marta Olsnes Kittang et al. (2013). The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine-the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. (ekstern lenke)
• Astrid Marta Olsnes Kittang; Kimberley Joanne Hatfield; Kristoffer Evebø Sand et al. (2010). The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications. (ekstern lenke)
• Guro Kristin Melve; Elisabeth Ersvær; Astrid Marta Olsnes Kittang et al. (2011). The chemokine system. in allogeneic stem-cell transplantation: a possible therapeutic target?. (ekstern lenke)
• Magnus Tobiasson; Astrid Marta Olsnes Kittang (2019). Treatment of myelodysplastic syndrome in the era of next-generation sequencing. (ekstern lenke)
• Håkon Reikvam; Kimberley Joanne Hatfield; Astrid Marta Olsnes Kittang et al. (2011). Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. (ekstern lenke)
• Øystein Bruserud; Astrid Marta Olsnes Kittang (2010). The chemokine system in experimental and clinical hematology. (ekstern lenke)

Doktorgradsavhandling

• Astrid Marta Olsnes Kittang (2008). The chemokine system in acute myelogenous leukemia. (ekstern lenke)
• Kristoffer Sand; Astrid Marta Olsnes Kittang (2015). Immunological aspects of myelodysplastic syndromes. (ekstern lenke)

Konferanseabstrakt

• Håkon Reikvam; Kimberley Joanne Hatfield; Astrid Marta Olsnes et al. (2009). PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. (ekstern lenke)
• Kristoffer Evebø Sand; Astrid Marta Olsnes Kittang; Øystein Bruserud (2010). Circulating T Cells Derived From Patients with Low Risk Myelodysplastic Syndromes Show Altered Chemokine Receptor Expression. (ekstern lenke)
• Astrid Marta Olsnes; Elisabeth Ersvær; Anita Ryningen et al. (2007). The protein kinase C activator PEP005 increases the chemokine release in native acute myelogenous leukemia (AML) blasts. (ekstern lenke)
• Astrid Marta Olsnes; Elisabeth Ersvær; Øystein Bruserud (2007). In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts: The chemokine release profile of the AML dendritic cells depends on the experimental protocol. (ekstern lenke)
• Astrid Marta Olsnes; Elisabeth Ersvær; Anita Ryningen et al. (2008). Chemokine receptor expression by circulating T cells derived from acute leukemia patients with severe chemotherapy-induced cytopenia express a wide range of chemokine receptors. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.